Reed Elsevier NV (ELSN.AS)
13.10EUR
11:35am EDT
€0.10 (+0.77%)
€12.99
€13.02
€13.12
€12.90
1,828,824
2,365,840
€13.57
€8.94
About
Overall
| Beta: | 0.45 |
| Market Cap (Mil.): | €20,003.12 |
| Shares Outstanding (Mil.): | 1,913.17 |
| Dividend: | 0.34 |
| Yield (%): | 3.59 |
Financials
| ELSN.AS | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 14.60 | 18.82 | 21.86 |
| EPS (TTM): | 0.89 | -- | -- |
| ROI: | 48.84 | 7.10 | 8.48 |
| ROE: | 48.61 | 10.24 | 12.86 |
Reed Elsevier's first quarter revenue growth in line with 2012
LONDON, April 24 - Anglo-Dutch publisher Reed Elsevier said first quarter underlying revenue growth was in line with last year and despite a mixed macro environment it expects to grow earnings in 2013.
UPDATE 1-Reed Elsevier sees growth in 2013
AMSTERDAM, Feb 28 - Anglo-Dutch publishing and events group Reed Elsevier expects a continued shift to electronic formats to help drive growth this year, and it has earmarked a further 300 million pounds ($454 million) for share buybacks.
Reed Elsevier 2012 results in line, sees growth in 2013
AMSTERDAM, Feb 28 - Anglo-Dutch publishing and events group Reed Elsevier reported full-year results in line with forecasts and said it expected further revenue and earnings growth this year.
Reed sells screening business to improve earnings
LONDON, Jan 17 - Reed Elsevier said on Thursday it had sold its LexisNexis screening business to a private equity group as part of a move to focus on assets with more predictable earnings and higher margins.
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Validea
|
$12.00
|
|
Provider: Zacks Investment Research Inc.
|
$12.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

